UniQure Announces First Two Patients Treated in Phase I/II Clinical Trial of AMT-130 for Treatment of Huntington's Disease
June 20, 2020
June 20, 2020
NEW YORK, June 20 -- The Huntington's Disease Society of America issued the following news:
UniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, announced that the first two patients in the Phase I/II clinical trial of AMT-130 for the treatment of Huntington's disease have been treated. The Phase I/II study is a double-blind, randomized clinical trial being conducted in the United States, with now one . . .
UniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, announced that the first two patients in the Phase I/II clinical trial of AMT-130 for the treatment of Huntington's disease have been treated. The Phase I/II study is a double-blind, randomized clinical trial being conducted in the United States, with now one . . .